Baxiva Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $63.3K

  • Investors
  • 6

Baxiva General Information

Description

Developer of glycoconjugate vaccines designed to combat serious bacterial infections and antimicrobial resistance. The company offers multivalent vaccines featuring a proprietary conjugation platform and novel linker chemistry that targets serotype-specific polysaccharides, enabling healthcare systems to prevent invasive Escherichia coli infections and reduce the clinical burden of urinary tract diseases and sepsis.

Contact Information

Website
www.baxiva.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Südstrasse 1
  • 8952 Schlieren
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Südstrasse 1
  • 8952 Schlieren
  • Switzerland

Baxiva Timeline

2026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Baxiva Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Accelerator/Incubator 15-Jun-2026 $63.3K Completed Startup
6. Seed Round 11-Feb-2026 Completed Startup
5. Accelerator/Incubator 22-Oct-2025 Completed Startup
4. Accelerator/Incubator 21-Aug-2025 Completed Startup
3. Accelerator/Incubator Completed Startup
2. Grant 17-Jun-2025 $10K Completed Startup
1. University Spin-Out 01-Jun-2025 Completed Startup
To view Baxiva’s complete valuation and funding history, request access »

Baxiva Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Baxiva Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Venture (Switzerland) Accelerator/Incubator
Gebert Rüf Foundation Accelerator/Incubator
CARB-X University
Venture Kick Accelerator/Incubator
ETH Zurich University
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Baxiva FAQs

  • When was Baxiva founded?

    Baxiva was founded in 2025.

  • Where is Baxiva headquartered?

    Baxiva is headquartered in Schlieren, Switzerland.

  • What is the size of Baxiva?

    Baxiva has 8 total employees.

  • What industry is Baxiva in?

    Baxiva’s primary industry is Drug Discovery.

  • Is Baxiva a private or public company?

    Baxiva is a Private company.

  • What is Baxiva’s current revenue?

    The current revenue for Baxiva is .

  • How much funding has Baxiva raised over time?

    Baxiva has raised $3.39M.

  • Who are Baxiva’s investors?

    Venture (Switzerland), Gebert Rüf Foundation, CARB-X, Venture Kick, and ETH Zurich are 5 of 6 investors who have invested in Baxiva.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process